... driver for global risk assets. The energy sector anticipates the monthly OPEC report and the EIA short-term outlook, while the agricultural markets are awaiting the August WASDE report. On the corporate side, a dense pool of reports from technology, biotech, and consumer companies in the U.S. is expected, alongside releases in Asia and on MOEX. Investors must evaluate the data in context: U.S. inflation ↔ Treasury yields ↔ dollar ↔ oil/commodities ↔ risk appetite. Macroeconomic Calendar (MSK) ...

... venture funds to realize profitable exits and redirect released capital into new projects. Despite investors' caution, the extended “window” encourages more startups to consider going public. Diversification of Investments: Fintech, Climate, and Biotech on the Rise In 2025, venture investments are being distributed across an increasingly broad range of sectors, rather than being concentrated solely in artificial intelligence. Following last year’s downturn, there is significant revitalization ...

... company's strategists emphasize growing investor interest in Russian pharmaceutical assets. Another example is “Ozon Pharmaceuticals”—a generic manufacturer from the Samara region—that announced IPO plans for the fall of 2024. In the narrower biotech segment, companies like “Betuvax” (vaccine “Betuvax-CoV-2”) and “Promomed” are mentioned; although they are more focused on biopharmaceuticals, their IPOs demonstrate a general interest in profile assets. The IPO strategy for such ...

... of the platform can take advantage of credit offerings from leading banks and purchase fuel with deferred payment. Transaction financing is facilitated by the largest banks in Russia. Learn more Diversification of Investments: Fintech, Climate, and Biotech on the Rise In 2025, venture investments are being distributed across an increasingly broad range of industries rather than being solely concentrated in AI. Following last year's downturn, there is a noticeable revival in fintech: major rounds ...

... sharply raised valuations of many companies. In the first half of 2025 alone, several dozen new unicorns (valued at over $1 billion) emerged, with some quickly reaching "ultra-unicorn" status (over $5 billion). Record investments in AI, fintech, biotech, and other innovative niches confirm a resurgence of investor confidence in promising technologies. Return of Mega Funds: Large Investors Refill the Market with Capital The largest investment players are triumphantly returning to the venture scene,...